Search

OBJ signs research agreement with GlaxoSmithKline Healthcare

Pharmaceutical giant GlaxoSmithKline Consumer Healthcare has signed a short term arrangement with Leederville-based transdermal drug delivery company OBJ Ltd to carry out studies into the use of its technology on a range of nonprescription applications.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

OBJ (OBJ)

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 31/08/18

1 year TSR5 year TSR
thThe Data Exchange Network0%0%
70thBotanix Pharmaceuticals140%105%
713thOBJ-48%10%
781st333D-62%-28%
737 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

15/05/18
$8k Bought
15/05/18
$9k Bought
09/05/18
$19k Bought
Total value as at the date of the transaction
Source: Morningstar

Revenue

137th-The Data Exchange Network$2.0m
138th↓OBJ$2.0m
140th↑333D$1.8m
141st↑Botanix Pharmaceuticals$1.8m
237 listed industrial companies ranked by revenue.
Source: Morningstar

Remuneration from OBJ

221stJeff Edwards$470k
606thChris Quirk$196k
Ranked by total remuneration from all listed WA companies

BNiQ Disclaimer